J. Jansen

发表

Efficacy, Tolerability and Safety of Oral Eletriptan and Ergotamine plus Caffeine (Cafergot®) in the Acute Treatment of Migraine: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Comparison

H. Diener, T. Steiner, D. Pitei, 2002, European Neurology.

OPIOIDS, SUBSTANCE ABUSE & ADDICTIONS SECTION Original Research Articles New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the

K. Simpson, M. Sanders, J. Jansen, 2016 .

New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects.

K. Simpson, M. Sanders, J. Jansen, 2015, Pain medicine.

Evaluation of guideline-adherent treatment in cluster headache

S. Evers, A. Frese, J. Jansen, 2016, Cephalalgia : an international journal of headache.

A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain

L. Webster, M. Jamal, M. Jamal, 2015, The American Journal of Gastroenterology.

Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial

H. Diener, A. Straube, H. Kaube, 2020, The Lancet Neurology.

A Randomized, Blind Comparison of Remifentanil and Alfentanil During Anesthesia for Outpatient Surgery

J. Cassuto, D. Noronha, D. Cartwright, 1997, Anesthesia and analgesia.

A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.

J. Wurzelmann, B. Lasko, E. Mortensen, 2011, The journal of pain : official journal of the American Pain Society.

Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open‐label, Phase 3b/4 Trial

R. Baron, A. Binder, I. Steigerwald, 2016, Pain practice : the official journal of World Institute of Pain.

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain

L. Webster, B. Morlion, J. Peppin, 2008, PAIN®.

SmartSenior - Intelligent Services for Senior Citizens

Joachim Hänsel, Norbert Pieth, Markus Schröder, 2012, Handbook of Ambient Assisted Living.

Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.

H. Diener, T. Steiner, D. Pitei, 2003, European neurology.

Survey to evaluate diagnosis and management of headache in primary care: Headache Management Pattern programme

N. Klippel, J. Jansen, J. Carlos, 2008, Current medical research and opinion.

A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain

L. Webster, M. Jamal, J. Jansen, 2015, The American Journal of Gastroenterology.

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain

L. Webster, B. Morlion, J. Peppin, 2008, PAIN®.